Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
GPR18 is a class A GPCR associated with the endocannabinoid system and immune function. It is highly expressed in immune cells and involved in various physiological processes, including immune regulation, pressure regulation, and pain modulation. Endogenous ligands include N-arachidonoylglycine (NAGly) and Resolvin D2 (RvD2). GPR18 has been implicated in several diseases, including immune disorders and cancer.
Gi/o protein activation (inhibition of adenylyl cyclase, reduced cAMP); Gq/11 protein activation (increased intracellular calcium)
3 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on G protein-coupled receptor 18 (GPR18).